BACKGROUND: Provoked vestibulodynia is a highly prevalent condition characterized by acute recurrent pain located at the vaginal entrance in response to pressure application or attempted vaginal penetration. Despite a wide variety of treatments offered to women with provoked vestibulodynia, a high proportion of women are refractory to conventional treatment. Transcranial direct-current stimulation is a noninvasive brain stimulation technique that has been shown effective for improving various chronic pain conditions. Growing evidence suggests that the central nervous system could play a key role in provoked vestibulodynia. Targeting the central nervous system could therefore be a promising treatment for women with provoked vestibulodynia. OBJECTIVE: The purpose of this study was to evaluate and compare the efficacy of active and sham transcranial direct-current stimulation in reducing pain intensity during intercourse in patients with provoked vestibulodynia. STUDY DESIGN: We conducted a triple-blind, parallel-group, randomized controlled trial. Women aged 17-45 years diagnosed with provoked vestibulodynia by a gynecologist using a validated protocol were randomized to 10 sessions of either active transcranial direct-current stimulation (intensity ¼ 2 mA) or 10 sessions of sham transcranial direct-current stimulation, over a 2-week period. Both active and sham transcranial direct-current stimulation were applied for 20 minutes, with the anode positioned over the primary motor cortex, and the cathode over the contralateral supraorbital area. Outcome measures were collected at baseline, 2 weeks after treatment, and at 3-month follow-up by an evaluator blinded to group assignment. The primary objective was to assess pain intensity during intercourse, using a numerical rating scale. Secondary outcomes focused on sexual function and distress, vestibular sensitivity, psychological distress, treatment satisfaction, and patient impression of change. Statistical analyses were conducted on the intention-totreat basis, and treatment effects were evaluated using a mixed linear model for repeated measures.
Introduction
Chronic pain associated with the female reproductive system is a neglected health problem. 1 By age 40 years, it is estimated that 8% of women will develop vulvar pain symptoms. 2 Provoked vestibulodynia (PVD), the most frequent cause of premenopausal dyspareunia, 3 is characterized by a recurrent sharp pain at the vulvar entrance (vestibule) in response to pressure or attempted vaginal penetration. The current medical approach for PVD relies on empirical treatment options, including localized (ie, topical lidocaine, physical therapy), systemic (ie, tricyclic antidepressants, anticonvulsants), psychotherapeutic (ie, cognitive behavioral therapy, sex therapy), and ultimately, surgical (vestibulectomy) interventions. 4 Women with PVD not only exhibit increased vulvar sensibility but also have a lower pain threshold and tolerance to other body regions, not restricted to the vestibule area. [5] [6] [7] Because of suggestions that PVD pathophysiology is not limited to the vulvar vestibule, central painprocessing alterations similar to other chronic pain syndromes such as fibromyalgia, 8, 9 irritable bowel syndrome, 10 and idiopathic back pain 11 might be involved. More recently, a neuromodulation treatment option, namely transcranial direct-current stimulation (tDCS), was proposed as another favorable therapeutic option for women with vulvodynia. 12 tDCS is a widely used painless noninvasive brain stimulation technique Related editorial, page 541.
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Original Research ajog.org using a low-intensity electrical current to modulate neuronal excitability. 13 Modulation of thalamocortical circuits could activate/reactivate descending inhibition systems, leading to nociception blocking.
14 Although the exact mechanisms underlying the effect of tDCS on pain perception are still unclear, a metaanalysis showed improvement in multiple chronic pain conditions using tDCS. 15 However, the evidence supporting the use of tDCS in this population is lacking. Treatments targeting the nervous system could be a promising therapeutic approach to reduce pain during intercourse for women with PVD given the central nervous system alterations postulated in this population. [5] [6] [7] To our knowledge, the effect of tDCS for reducing pain in women with vulvodynia has been documented in only one case study, 16 which described remarkable long-lasting pain relief using tDCS in a woman with severe chronic vulvar pain refractory to many empirical treatments. Based on observations of Cecilio et al, 16 it could be hypothesized that active tDCS treatment compared to sham would significantly reduce pain during intercourse in women with PVD (2-week posttreatment and 3-month follow-up compared to baseline assessment).
The main purpose of this study was to evaluate and compare the efficacy of active and sham tDCS in reducing pain intensity during intercourse with PVD. We also compared the effects of both interventions for sexual function, vestibular sensitivity, psychological distress, treatment satisfaction, and Patient Global Impression of Change (PGIC).
Materials and Methods

Study design
A triple-blind (assessor, patient, and treatment provider) randomized placebo-controlled trial was conducted. Eligible women were randomly assigned to receive either active or sham tDCS. Outcome assessments were conducted at baseline, 2 weeks after treatment, and 3 months after treatment. The study protocol received ethical approval from the Comité d'éthique de la recherche en santé chez l'humain du Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Québec, Canada. Each participant provided written informed consent before participating in the study. The study protocol was registered at clinicaltrials.gov (NCT02543593) and published in the journal Trials.
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Participants
Premenopausal women aged 17-40 years with pain during sexual intercourse were recruited at the Research Center of the Centre hospitalier universitaire de Sherbrooke from November 2014 through February 2016. Participants' eligibility was first authenticated during a telephone interview with the research coordinator. Thereafter, to further assess eligibility and confirm PVD diagnosis, a gynecological assessment was performed by a gynecologist of the research team (G.W., Y-A.B., or I.G.) following a standardized protocol including a cotton swab test (recommended for evaluating vestibular tenderness and reproducibility with symptoms experienced during intercourse). 18, 19 Patients were eligible if, in the last 6 months, they experienced moderate to severe pain (>5/10) in at least 90% of attempted sexual intercourse. Also, those included needed to have a stable sexual partner to be able to experience vaginal penetrations to evaluate their pain intensity. Those with other urogynecological conditions (eg, urinary tract or vaginal infection), pelvic pathology associated with pelvic pain (eg, deep dyspareunia), uncontrolled health issues, or contraindications to tDCS (ie, history of epilepsy) were excluded from participating in the study. Those who refused to abstain from other treatments related to PVD during their enrollment in the study were also excluded (See Morin et al 17 for more details on eligibility). Partipants selection, randomization, and assessments Participants were randomly assigned to active tDCS or sham tDCS in a 1:1 ratio. Some women had multiple reasons for ineligibility.
Intervention
Participants were randomized to receive 10 sessions of either active/anode or sham/placebo tDCS over a period of 14 days. tDCS treatments were given once a day, on weekdays (Monday through Friday). Each session lasted 20 minutes [20] [21] [22] [23] [24] and administered by a research professional experienced in tDCS. The treatment provider was not involved in patient assessment and was blinded to the treatment allocation by selecting a preset program of the tDCS device (DC stimulator, model 0008; neuroConn GmbH, Ilmenau, Germany). Two electrodes were applied to the subject's scalp; the anode was placed over the motor cortex (M1) 25 and the cathode over the contralateral supraorbital area. [20] [21] [22] 24, 25 Saline solution (77 mmol/L sodium chloride) was used to soak the synthetic sponge electrode covers (35 cm 2 ). For the active tDCS condition, the intensity of the stimulation was set at 2 mA for the entire duration of treatment. 16, 20, 26 These parameters have been used with many subjects in several laboratories without side effects 27 apart from a slight sensation and erythema under the electrodes and possible headache in the hours following the treatment. For the sham tDCS condition, the electrodes were positioned in the same areas as for the active group. The intensity was set at 2 mA for the first 30 seconds of treatment, 24 after which the stimulation stopped automatically. Just as for the experimental group (active tDCS), participants in the control group (sham tDCS) were advised that a brief tingling sensation may be felt at the beginning of the treatment. This method was effective for preserving subject and investigator blinding in previous studies. 28, 29 
Data collection
Outcome assessment As recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials, 30, 31 multiple dimensions of pain were targeted to adequately evaluate the effectiveness of tDCS in reducing pain during intercourse in female patients with PVD. Baseline characteristics were collected during a structured interview at pretreatment assessment. Assessments were collected at baseline, 2 weeks after treatment, and follow-up, except for patient treatment satisfaction and impression of change (collected after the end of treatments only). At the end of the follow-up assessment, participants and treatment provider were separately asked to guess whether active or sham treatment was administered. Participants received CAD $20 after each assessment visit for a possible total of CAD $60.
Pain during intercourse
Participants were asked to evaluate their mean pain intensity during intercourse since the last assessment on a 0-10 verbal numeric rating scale, 0 being no pain, and 10 the worst pain ever experienced.
Questionnaires
Standardized validated questionnaires including pain quality (McGill-Melzack Pain Questionnaire), 32, 33 sexual functioning (Female Sexual Function Index), 34 sexual distress (Female Sexual Distress Scale), 35 sexual satisfaction (Global Measure of Sexual Satisfaction), 36 and patient treatment satisfaction and impression of change (PGIC questionnaire) 37, 38 were completed. Psychological distress was assessed using questionnaires focusing on vaginal penetration (Vaginal Penetration 41, 42 and depression (Beck Depression Inventory). 43 
Vestibular sensitivity
The third International Consultation on Sexual Medicine underlined the importance of assessing vestibular sensitivity. 44 Our laboratory recently developed an algometer to measure vulvar pain threshold and tolerance in PVD. 45 A gradual pressure (0-1000 g) was applied to 3 distinct points of the vestibule at the 3, 6, and 9 o'clock positions. 45 Each pressure point was applied randomly (eg, 3,6,9 or 3,9,6 or 6,9,3). During this procedure, each participant was asked to indicate when they started to feel pain (pressure pain threshold) and, subsequently, the maximal pressure they could tolerate (pressure pain tolerance). 46 Both pressure pain threshold and pressure pain tolerance were identified using a computerized visual analog scale throughout the test. Pressure pain threshold was determined when the participant started to move the computerized visual analog scale from 0 (no pain), and pressure pain tolerance was established when the participant reached 10 (most intense pain tolerable). This assessment has shown good reliability and validity. 45 
Adverse events
To report participants' adverse events during tDCS treatment, at each treatment session, the treatment provider noted participants' side effects; subjects were also asked to report any adverse events experienced during or after each tDCS session in a 2-week diary.
Sample size calculation
A sample size of 34 participants was judged sufficient to detect a clinical minimal significant difference of 2 30, 47 on the numeric rating scale (a ¼ 0.05; b ¼ 0.80, SD 2.0, based on data from previous tDCS reports 24, 48 ). This estimation of treatment effect was conservative considering that tDCS demonstrated an overall effect on pain reduction of 4.3 points 15 in various types of chronic pain and that the available case study in a participant with vulvodynia showed a reduction of 10 points. 16 To account for potential dropouts, a total of 40 subjects were recruited. This estimated dropout rate (<15%) was based on available studies and our own randomized controlled trial (RCT) experience in patients with PVD. [49] [50] [51] Randomization and blinding
After the baseline assessment, participants were randomized into either active or sham tDCS treatment (ratio 1:1) using randomly permuted block sizes of 2 and 4. The allocation was managed by an independent clinical associate following a computer-generated randomization list drawn up by an independent statistician. Participants, investigators, physiotherapist assessors, and treatment provider remained blinded to group allocation and therefore could not influence the process in any way.
Statistical analysis
Baseline sample characteristics are presented using descriptive statistics. Analyses were done in intention-to-treat. The effects of treatment on pain, sexual function, and psychological distress were examined using a mixed linear model for repeated measures. One of the factors was the group (treatment group: active tDCS and control group: sham tDCS), while the repeated factor was time (baseline, 2-week posttreatment, and 3-month follow-up assessments). Treatment efficacy was judged on the basis of a significant group*time interaction. 52 For some data sets, logarithmic transformation was required to correct the distribution of residuals to normal (pain quality, vaginal control cognition, anxiety state, depression, and algometer). After analysis, results were converted back to their original scale. The difference between the 2 groups regarding satisfaction and PGIC was also assessed using mixed linear model for repeated measures. Owing to the relatively small number of participants included in the study and in spite of histograms 
Pain intensity by treatment group
Numeric rating scale (NRS) of mean pain intensity during intercourse at baseline, post-treatment, and follow-up assessments. *P .05, **P .01, ***P .001: difference from baseline. 
Results Participants
A total of 202 patients were screened for study eligibility from November 2014 through February 2016. Of these, 111 were excluded due to ineligibility, and 42 refused to participate prior to gynecological assessment. Another 6 were excluded at the gynecologist assessment due to deep dyspareunia diagnosis (n ¼ 3), and negative cotton swab test (n ¼ 3). After receiving their PVD diagnosis, an additional 3 refrained from taking part in the study. As a result, 40 participants were consented, scheduled for baseline assessment, randomly assigned to receive active tDCS (n ¼ 20) or sham tDCS (n ¼ 20), and rescheduled for 2-week and follow-up assessments. One participant's data could not be considered in the analyses because she did not attempt any vaginal penetration after receiving treatments. All participants adhered fully to study treatment and assessments as planned in the study protocol. Neither the active nor the sham group received other therapeutic interventions during the study. tDCS was the first treatment attempt for 19 participants, whereas 21 wanted to participate in the study because they were still experiencing pain during intercourse after previous attempted treatment(s). Figure 1 shows the trial flow diagram. Baseline characteristics are presented in Table 1 . Participant characteristics were well matched for both treatment groups with regard to age, education, civil status, pain intensity and frequency, age at first intercourse attempt, number of sexual partners, relationship and pain duration, PVD subtype, and use of oral contraceptives.
Primary outcome
Mean pain intensity scores during intercourse for each assessment are illustrated in Figure 2 . Women assigned to both interventions reported a significant pain intensity reduction from baseline to posttreatment assessment (reduction of 1.2 points in active; 95% confidence interval [CI], 0.4e2.1; P ¼.03 and 1.8; 95% CI, 0.8e2.8 in sham tDCS; P ¼ .001). In addition, those assigned to sham treatment reported a significant pain intensity reduction from baseline to follow-up assessment (reduction of 2.5 points; 95% CI, 1.4e3.7; P < .001). However, there was no statistically significant difference between treatment groups at each assessment (P ¼.84 and .09, respectively).
Secondary outcomes
No significant differences were found at baseline between the 2 groups in the secondary outcomes except for stateanxiety, which was higher in the active tDCS group than in the placebo group ajog.org GYNECOLOGY Original Research (Table 2) . A significant reduction of sexual distress, catastrophizing, pain anxiety, and improvement in sexual function were observed in both treatments from baseline to follow-up assessments. Again, there was no statistical difference between those assigned to active and sham tDCS (P values > .08).
Even though there was a significant difference between groups at posttreatment in catastrophizing (P ¼.02), pain anxiety (P ¼ .03), and at follow-up in pain quality (P ¼ .004), active tDCS did not result in a significant advantage in any measured outcome at any time point, compared to sham tDCS. Questionnaire scores are presented in Table 2 . Interestingly, patient treatment satisfaction and impression of change were similar between groups (P values > .14).
As shown in Table 3 , compared to sham, active tDCS did not significantly improve vestibular sensitivity (pressure pain threshold and pressure pain tolerance) in any assessment (P values > .07). In fact, pressure pain tolerance measured at the 6 o'clock position at follow-up assessment was higher in the sham group (P ¼ .02).
Blinding integrity
Treatment blinding was effective for participants but not for the tDCS operator (Table 4) . In all, 42% in the active group and 45% in the sham group correctly identified which treatment they Original Research GYNECOLOGY ajog.org received (P ¼.5). 29, 48 However, the tDCS operator correctly identified active treatment in 84%, and sham treatment in 60% of cases (P ¼ .008).
Adverse effects
Mild and transitory side effects, commonly found in the literature for tDCS intervention, 27 were reported by participants in both groups (Table 5) . During treatment sessions, participants assigned to sham treatment reported more tingling sensation under the cathode (P ¼ .02), while a burning sensation under the cathode and erythema 27 under the anode were observed more often by participants assigned to active treatment (both P ¼ .04). On the other hand, there was no difference between groups regarding reported adverse events between treatment sessions, such as fatigue (P ¼.30), headache (P ¼.60), 27 dizziness (P ¼ .50), or nausea (P ¼ .20).
Comment
To our knowledge, this is the first RCT evaluating tDCS efficacy for reducing pain in women with PVD. Our results show that active tDCS does not significantly reduce pain during intercourse or improve sexual function or distress, vestibular sensitivity, or psychological distress compared to sham/ placebo.
Although tDCS has been shown effective to reduce pain in multiple chronic pain conditions, 21, 22, 26, [53] [54] [55] its efficacy to reduce pain during intercourse in women with PVD was not substantiated. While those assigned to sham treatment reported a clinically significant pain intensity reduction from baseline to follow-up assessment (reduction of 2.5 points), this was not observed in the active group. Notably, the pain intensity reduction did not significantly or clinically differ between groups. The absence of group difference is not a sample size issue, as we had adequate statistical power to detect clinically relevant differences; hence type II error is not a valid explanation for our findings.
Our results coincide with a recently updated Cochrane review now showing no significant difference between active and sham tDCS in chronic pain reduction. 13 Our trial also challenges the observation of tDCS efficacy in reducing vulvar pain as published by Cecilio et al. 16 However, it must be highlighted that the woman described in the latter's case study had generalized unprovoked vulvodynia. Because these are 2 different subtypes of vulvodynia, it is possible that tDCS might be effective in one condition 16 than for provoked pain conditions like PVD.
Mechanisms underlying placebo analgesia are only partly understood. It has been shown that expectation of relief contributes to placebo responses. [57] [58] [59] Another possible explanation is the support provided throughout the study. PVD is indeed a meaningful threat that interferes with many aspects of women's lives (ie, sexual satisfaction, sexual selfesteem, psychological and sexual distress). 60 Given that PVD is often misdiagnosed or even ignored, those participating in our study had prompt access to a gynecologist, which should normally take at least a year in Quebec's health care system. Meeting the same physiotherapist at each assessment and the same treatment provider on a daily basis over a 2-week periodeboth women specializing in vulvar paineallowed participants to discuss their sexual problem with confidence. This may partially explain the changes observed in both interventions for sexual functioning, sexual distress, catastrophizing, and pain anxiety. Behavioral approaches such as systematic desensitization and attentive listening were, respectively, found to be effective for pain management in vaginismus 61 and in the elderly.
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A substantial proportion of women with PVD are reported to present pain hypersensitivity in both vulvar [5] [6] [7] and extragenital regions (ie, forearm, arm, fingers, thigh, shin), 6, 7 suggesting that not only peripheral sensitization but also generalized central abnormalities are involved in PVD. 63 As proposed by Zhang et al, 64 similar chronic pain alterations exist in several patients with vulvodynia. However, in their publication, the authors did not distinguish women with provoked pain from those with unprovoked pain. To determine whether PVD subgroups can benefit more than others from tDCS, the relationship between the hypoalgesic effect noted after tDCS treatments and other variables such as emotional component of pain and central processing alteration should be investigated.
The strength of our study relies on its rigorous methodology. We minimized potential bias by including a recommended credible sham treatment, randomizing treatment allocation, and blinding the participants, treatment provider, outcome assessor, and statistician. In addition, to avoid information bias, we followed several authors' suggestions 65, 66 to prevent the treatment assessor blinding from being compromised at 2-mA intensity. Therefore, in our study, the treatment provider was not involved in any outcome assessments. Despite all these efforts made to minimize bias, our trial still had some limitations. Menstrual cycle was not controlled during the study, even though it is known that pain perception changes across the menstrual cycle. 67 However, this variability in subject's pain evaluation and perception should be balanced between groups due to randomized treatment allocation. Another limitation might be attributable to inconsistency in pain evaluation and information bias, especially when the participant had to recall relatively distant experiences. To counterbalance this potential memory bias, subjects were asked to complete a 4-week logbook (during the treatment period and 2 weeks after) in which they had to report if they experienced any pain in the vulvar region, whether or not related to intercourse.
Conclusion
Active tDCS did not confer benefits over sham tDCS in pain or function in women with PVD. Although it remains possible that a subpopulation of patients with PVD could benefit from tDCS, our findings do not support the use of tDCS for these patients. n
